← Human Trials & Peer-Reviewed Studies
Trial of preventing hypertension: design and 2-year progress report.
Plain-language guide to PMID 15238567 (2004): double-blind randomized controlled trial of Angiotensin II Type 1 Receptor Blockers in 809 subjects.
Key Facts
- PMID
- 15238567
- Journal
- Hypertension (Dallas, Tex. : 1979)
- Year
- 2004
- Study type
- Randomized Controlled Trial
- Authors
- Julius S et al. (7 authors)
- DOI
- 10.1161/01.HYP.0000130174.70055.ca
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II Type 1 Receptor Blockers in this randomized controlled trial publication.
This is a 4-year, multicenter, randomized, double-blind study in untreated subjects aged 30 to 65 years with entry BPs of 130 to 139/< or =89 or < or =139/85 to 89.
The main outcome measure was the development of clinical (treatment-requiring) hypertension assessed by an automated (blinded) BP measurement device.
Who Took Part
According to the abstract, 809 subjects were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
Because people in this Angiotensin II Type 1 Receptor Blockers study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the subjects nor the staff measuring them knew who was on Angiotensin II Type 1 Receptor Blockers, so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Angiotensin II Type 1 Receptor Blockers group a baseline to be compared against.
More than one site took part, so the subjects came from several places.
What Was Measured
The main outcome measure was the development of clinical (treatment-requiring) hypertension assessed by an automated (blinded) BP measurement device.
Topics PubMed links to this paper include Angiotensin II Type 1 Receptor Blockers, Benzimidazoles, Biphenyl Compounds, Hypertension and Tetrazoles.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II Type 1 Receptor Blockers in 809 subjects.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2004 (Hypertension (Dallas, Tex. : 1979)), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.